CK Life Sciences Int'l., (Holdings) Inc. (00775.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

142.1x

Market Cap

HKD 5.74B

MomentumView details →

1D Return

+0.85%

YTD Return

−28.05%

RSI (14)

50.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

142.1x

Market Cap

HKD 5.74B

RSI (14)

50.8

MomentumView details →

1D Return

+0.85%

YTD Return

−28.05%

ProfitabilityView details →

Gross Margin

22.03%

Net Margin

−3.13%

EBITDA Margin

0.78%

ROE (TTM)

−8.73%

ROA (TTM)

−2.83%

Asset Turnover

0.92x

GrowthView details →

Revenue YoY

+2.99%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+0.84%

EPS CAGR 3Y

−46.97%

EBITDA YoY

−89.11%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.73x

Current Ratio

0.91x

Quick Ratio

0.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

−20.00%

Financials snapshotView financials →

Revenue (TTM)

11.01B

Net Income (TTM)

−344.73M

Op. CF (TTM)

125.36M

Latest newsMore news →

CK Life Sciences International reported interim results for the six months ended June 2026, with revenue of HK$2.716 billion, up 4.2% year-on-year, and a narrowed net loss of HK$28.73 million, compared with a loss of HK$151 million in the same period last year.24d ago

Similar companies

Ligand Pharmaceuticals IncorporatedLGND Xenon Pharmaceuticals Inc.XENE PTC Therapeutics, Inc.PTCT Erasca, Inc.ERAS 悦康药业688658.SH Abbisko Cayman Limited02256.HK Find similar companies →

Latest newsMore news →

CK Life Sciences International reported interim results for the six months ended June 2026, with revenue of HK$2.716 billion, up 4.2% year-on-year, and a narrowed net loss of HK$28.73 million, compared with a loss of HK$151 million in the same period last year.24d ago